{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:40:31Z","timestamp":1793324431227,"version":"4.5.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meningiomas are the most frequent primary intracranial tumors. Hence, they constitute a major share of diagnostic specimens in neuropathology practice. The 2021 WHO Classification of Central Nervous System Tumors (\u201cCNS5\u201d) has introduced the first molecular grading parameters for meningioma with oncogenic variants in the TERT promoter and homozygous deletion of CDKN2A\/B as markers for CNS WHO grade 3. However, after the publication of the new classification volume, clarifications were requested, not only on novel but also on long-standing questions in meningioma grading that were beyond the scope of the WHO \u201cblue book.\u201d In addition, more recent research into possible new molecular grading parameters could not yet be implemented in the 2021 classification but constitutes a compelling body of literature. Hence, the consortium to inform molecular and practical approaches to CNS tumor taxonomy-not official WHO (cIMPACT-NOW) Steering Committee convened a working group to provide such clarification and assess the evidence of possible novel molecular criteria. As a result, this cIMPACT-NOW update provides guidance for more standardized morphological evaluation and interpretation, most prominently pertaining to brain invasion, identifies scenarios in which advanced molecular testing is recommended, proposes to assign CNS WHO grade 2 for cases with CNS WHO grade 1 morphology but chromosomal arm 1p deletion in combination with 22q deletion and\/or NF2 oncogenic variants, and discusses areas in which the current evidence is not yet sufficient to result in new recommendations.<\/jats:p>","DOI":"10.1093\/neuonc\/noae170","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T09:39:20Z","timestamp":1725010760000},"page":"319-330","source":"Crossref","is-referenced-by-count":141,"title":["cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1962","authenticated-orcid":false,"given":"Felix","family":"Sahm","sequence":"first","affiliation":[{"name":"CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]},{"name":"Department of Neuropathology, University Hospital Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D","family":"Aldape","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4470-8425","authenticated-orcid":false,"given":"Priscilla K","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Divisions of Hematology\/Oncology and Neuro-Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Brat","sequence":"additional","affiliation":[{"name":"Department of Pathology, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-0964","authenticated-orcid":false,"given":"Sonika","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-540X","authenticated-orcid":false,"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-6782","authenticated-orcid":false,"given":"Caterina","family":"Giannini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum , Bologna ,","place":["Italy"]},{"name":"Department of Laboratory Medicine\/Pathology and Neurosurgery, Mayo Clinic College of Medicine, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Brigham and Women\u2019s Hospital, and Harvard Medical School , Boston Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology, Neurological Surgery, and Pathology, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Reifenberger","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK) Partner Site Essen\/D\u00fcsseldorf , D\u00fcsseldorf ,","place":["Germany"]},{"name":"Institute of Neuropathology, University Hospital D\u00fcsseldorf and Medical Faculty, Heinrich Heine University D\u00fcsseldorf , D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Santagata","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6637-4502","authenticated-orcid":false,"given":"Gelareh","family":"Zadeh","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Wesseling","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology , Utrecht ,","place":["The Netherlands"]},{"name":"Department of Pathology, Amsterdam University Medical Centers \/ VU University , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Perry","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Neurological Surgery, UCSF , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"1","key":"2025021113135005800_CIT0001","first-page":"4","article-title":"The cIMPACT-NOW updates and their significance to current neuro-oncology practice","volume":"8","author":"Gonzalez Castro","year":"2021","journal-title":"Neurooncol. Pract.."},{"issue":"12","key":"2025021113135005800_CIT0002","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/00000478-199712000-00008","article-title":"Meningioma grading: an analysis of histologic parameters","volume":"21","author":"Perry","year":"1997","journal-title":"Am J Surg Pathol."},{"issue":"9","key":"2025021113135005800_CIT0003","first-page":"2046","article-title":"\u201cMalignancy\u201d in meningiomas: a clinicopathologic study of 116 patients, with grading implications","volume":"85","author":"Perry","year":"1999","journal-title":"Cancer."},{"issue":"9","key":"2025021113135005800_CIT0004","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41379-021-00825-7","article-title":"Counting mitoses: SI(ze) matters!","volume":"34","author":"Cree","year":"2021","journal-title":"Mod Pathol."},{"issue":"3","key":"2025021113135005800_CIT0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-019-03312-x","article-title":"Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome","volume":"145","author":"Biczok","year":"2019","journal-title":"J Neurooncol."},{"issue":"6","key":"2025021113135005800_CIT0006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/nan.12700","article-title":"The prognostic significance of clinicopathological features in meningiomas: Microscopic brain invasion can predict patient outcome in otherwise benign meningiomas","volume":"47","author":"Banan","year":"2021","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"3","key":"2025021113135005800_CIT0007","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00401-016-1598-1","article-title":"Brain invasion in otherwise benign meningiomas does not predict tumor recurrence","volume":"132","author":"Baumgarten","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"8","key":"2025021113135005800_CIT0008","article-title":"The definition and role of brain invasion in meningioma grading: Still controversial after all these years","volume":"2","author":"Perry","year":"2021","journal-title":"Free Neuropathol"},{"issue":"26","key":"2025021113135005800_CIT0009","doi-asserted-by":"crossref","first-page":"14719","DOI":"10.1073\/pnas.94.26.14719","article-title":"Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression","volume":"94","author":"Weber","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2025021113135005800_CIT0010","first-page":"354","article-title":"Brain invasion assessability in meningiomas is related to meningioma size and grade, and can be improved by extensive sampling of the surgically removed meningioma specimen","volume":"33","author":"Pizem","year":"2014","journal-title":"Clin Neuropathol."},{"key":"2025021113135005800_CIT0011","doi-asserted-by":"crossref","first-page":"101740","DOI":"10.1016\/j.bas.2023.101740","article-title":"Differences in intraoperative sampling during meningioma surgery regarding CNS invasion - Results of a survey on behalf of the EANS skull base section","volume":"3","author":"Behling","year":"2023","journal-title":"Brain Spine."},{"issue":"10","key":"2025021113135005800_CIT0012","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/neuonc\/nox071","article-title":"Brain invasion in meningiomas-clinical considerations and impact of neuropathological evaluation: A systematic review","volume":"19","author":"Brokinkel","year":"2017","journal-title":"Neuro Oncol."},{"issue":"2","key":"2025021113135005800_CIT0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/bpa.12110","article-title":"High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression","volume":"24","author":"Goutagny","year":"2014","journal-title":"Brain Pathol."},{"issue":"5","key":"2025021113135005800_CIT0014","doi-asserted-by":"crossref","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","article-title":"TERT promoter mutations and risk of recurrence in meningioma","volume":"108","author":"Sahm","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"65","key":"2025021113135005800_CIT0015","doi-asserted-by":"crossref","first-page":"109228","DOI":"10.18632\/oncotarget.22650","article-title":"Intratumoral heterogeneity and TERT promoter mutations in progressive\/higher-grade meningiomas","volume":"8","author":"Juratli","year":"2017","journal-title":"Oncotarget."},{"issue":"2","key":"2025021113135005800_CIT0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0002-9440(10)61737-3","article-title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas","volume":"159","author":"Bostrom","year":"2001","journal-title":"Am J Pathol."},{"issue":"3","key":"2025021113135005800_CIT0017","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1023\/A:1013863630293","article-title":"Alterations of INK4a(p16-p14ARF)\/INK4b(p15) expression and telomerase activation in meningioma progression","volume":"55","author":"Simon","year":"2001","journal-title":"J Neurooncol."},{"issue":"2","key":"2025021113135005800_CIT0018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1750-3639.2002.tb00433.x","article-title":"A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas","volume":"12","author":"Perry","year":"2002","journal-title":"Brain Pathol."},{"issue":"6","key":"2025021113135005800_CIT0019","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/ijc.11013","article-title":"Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome","volume":"104","author":"Korshunov","year":"2003","journal-title":"Int J Cancer."},{"issue":"3","key":"2025021113135005800_CIT0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2025021113135005800_CIT0021","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00401-023-02543-7","article-title":"Even heterozygous loss of CDKN2A\/B greatly accelerates recurrence in aggressive meningioma","volume":"145","author":"Khan","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2025021113135005800_CIT0022","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol."},{"issue":"4","key":"2025021113135005800_CIT0023","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00401-023-02544-6","article-title":"Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas","volume":"145","author":"Tang","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2025021113135005800_CIT0024","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnen\/nlab127","article-title":"Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas: A single center cohort study","volume":"81","author":"Sasaki","year":"2022","journal-title":"J Neuropathol Exp Neurol."},{"issue":"6","key":"2025021113135005800_CIT0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cancergen.2015.03.005","article-title":"ARID1A and TERT promoter mutations in dedifferentiated meningioma","volume":"208","author":"Abedalthagafi","year":"2015","journal-title":"Cancer Genet."},{"issue":"6330","key":"2025021113135005800_CIT0026","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1126\/science.aam7304","article-title":"The cancer epigenome: Concepts, challenges, and therapeutic opportunities","volume":"355","author":"Dawson","year":"2017","journal-title":"Science."},{"issue":"1","key":"2025021113135005800_CIT0027","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41467-019-09140-x","article-title":"H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2\/me3 and is essential for glioma tumorigenesis","volume":"10","author":"Harutyunyan","year":"2019","journal-title":"Nat Commun."},{"issue":"366","key":"2025021113135005800_CIT0028","doi-asserted-by":"crossref","first-page":"366ra","DOI":"10.1126\/scitranslmed.aah6904","article-title":"Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas","volume":"8","author":"Bayliss","year":"2016","journal-title":"Sci Transl Med."},{"issue":"1","key":"2025021113135005800_CIT0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2015.134","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","journal-title":"Mod Pathol."},{"issue":"6","key":"2025021113135005800_CIT0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00401-018-1844-9","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"8","key":"2025021113135005800_CIT0031","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/neuonc\/noab036","article-title":"Loss of H3K27me3 in meningiomas","volume":"23","author":"Nassiri","year":"2021","journal-title":"Neuro Oncol."},{"key":"2025021113135005800_CIT0032","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.humpath.2021.06.005","article-title":"The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma","volume":"115","author":"Jung","year":"2021","journal-title":"Hum Pathol."},{"issue":"8","key":"2025021113135005800_CIT0033","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noaa303","article-title":"H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort","volume":"23","author":"Behling","year":"2021","journal-title":"Neuro Oncol."},{"issue":"7","key":"2025021113135005800_CIT0034","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnen\/nlaa038","article-title":"Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: A multicenter retrospective study","volume":"79","author":"Gauchotte","year":"2020","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"2025021113135005800_CIT0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11060-022-04169-3","article-title":"Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk","volume":"161","author":"Hua","year":"2023","journal-title":"J Neurooncol."},{"key":"2025021113135005800_CIT0036","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.wneu.2022.04.048","article-title":"The emerging relevance of H3K27 trimethylation loss in meningioma: A systematic review of recurrence and overall survival with meta-analysis","volume":"163","author":"Lu","year":"2022","journal-title":"World Neurosurg"},{"issue":"1","key":"2025021113135005800_CIT0037","first-page":"vdad112","article-title":"Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2","volume":"5","author":"Behling","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"4","key":"2025021113135005800_CIT0038","first-page":"535","article-title":"Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol."},{"issue":"11","key":"2025021113135005800_CIT0039","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/nox094","article-title":"BAP1 mutations in high-grade meningioma: implications for patient care","volume":"19","author":"Shankar","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"2025021113135005800_CIT0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00401-020-02161-7","article-title":"Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features","volume":"140","author":"Williams","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2025021113135005800_CIT0041","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40478-020-01040-2","article-title":"Distinct genomic subclasses of high-grade\/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic","volume":"8","author":"Williams","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"2025021113135005800_CIT0042","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ng.2552","article-title":"Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas","volume":"45","author":"Smith","year":"2013","journal-title":"Nat Genet."},{"issue":"2","key":"2025021113135005800_CIT0043","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10048-015-0472-y","article-title":"A heritable form of SMARCE1-related meningiomas with important implications for follow-up and family screening","volume":"17","author":"Gerkes","year":"2016","journal-title":"Neurogenetics"},{"issue":"4","key":"2025021113135005800_CIT0044","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bpa.12524","article-title":"Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: A comprehensive immunophenotypical and molecular analysis","volume":"28","author":"Tauziede-Espariat","year":"2018","journal-title":"Brain Pathol."},{"issue":"12","key":"2025021113135005800_CIT0045","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/jnen\/nlz091","article-title":"Distinct expression patterns of carbonic anhydrase IX in clear cell, microcystic, and angiomatous meningiomas","volume":"78","author":"Chkheidze","year":"2019","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"2025021113135005800_CIT0046","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00401-020-02247-2","article-title":"Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1","volume":"141","author":"Sievers","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"6123","key":"2025021113135005800_CIT0047","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science."},{"issue":"2","key":"2025021113135005800_CIT0048","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2017.168","article-title":"Advances in meningioma genetics: novel therapeutic opportunities","volume":"14","author":"Preusser","year":"2018","journal-title":"Nat Rev Neurol."},{"issue":"6","key":"2025021113135005800_CIT0049","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CCO.0000000000000687","article-title":"Molecular alterations in meningioma: Prognostic and therapeutic perspectives","volume":"32","author":"Birzu","year":"2020","journal-title":"Curr Opin Oncol."},{"issue":"3","key":"2025021113135005800_CIT0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet."},{"issue":"10","key":"2025021113135005800_CIT0051","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark","year":"2016","journal-title":"Nat Genet."},{"issue":"5","key":"2025021113135005800_CIT0052","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol."},{"issue":"5","key":"2025021113135005800_CIT0053","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/noaa226","article-title":"Associations of meningioma molecular subgroup and tumor recurrence","volume":"23","author":"Youngblood","year":"2021","journal-title":"Neuro Oncol."},{"issue":"3","key":"2025021113135005800_CIT0054","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","article-title":"Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations","volume":"125","author":"Reuss","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2025021113135005800_CIT0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00401-022-02485-6","article-title":"Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7\/AKT1 and TRAF7\/KLF4 mutant meningiomas","volume":"144","author":"Dogan","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"7","key":"2025021113135005800_CIT0056","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/modpathol.2016.81","article-title":"Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system","volume":"29","author":"Yuzawa","year":"2016","journal-title":"Mod Pathol."},{"issue":"5","key":"2025021113135005800_CIT0057","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2025021113135005800_CIT0058","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3171\/2016.8.JNS161076","article-title":"Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas","volume":"127","author":"Strickland","year":"2017","journal-title":"J Neurosurg."},{"issue":"5","key":"2025021113135005800_CIT0059","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood","year":"2019","journal-title":"J Neurosurg."},{"issue":"2","key":"2025021113135005800_CIT0060","doi-asserted-by":"crossref","first-page":"e12970","DOI":"10.1111\/bpa.12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff","year":"2022","journal-title":"Brain Pathol."},{"issue":"7874","key":"2025021113135005800_CIT0061","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature."},{"issue":"5","key":"2025021113135005800_CIT0062","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"3","key":"2025021113135005800_CIT0063","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: Phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5110","key":"2025021113135005800_CIT0064","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/216084a0","article-title":"Chromosomal consitution of meningiomas","volume":"216","author":"Zang","year":"1967","journal-title":"Nature."},{"issue":"1","key":"2025021113135005800_CIT0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-4608(89)90143-X","article-title":"Karyotypic evolution of human meningioma. Progression through malignancy","volume":"40","author":"Casartelli","year":"1989","journal-title":"Cancer Genet Cytogenet."},{"issue":"2","key":"2025021113135005800_CIT0066","first-page":"119","article-title":"Loss of 1p in recurrent meningiomas. a comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization","volume":"125","author":"Lopez-Gines","year":"2001","journal-title":"Cancer Genet Cytogenet."},{"key":"2025021113135005800_CIT0067","first-page":"1","article-title":"[The karyotype of the meningioma.Studies on the relations between chromosome set and tumor development (author\u2019s transl)]","volume":"111","author":"Zankl","year":"1979","journal-title":"Veroff Pathol."},{"issue":"6","key":"2025021113135005800_CIT0068","first-page":"1601","article-title":"Clonal cytogenetic progression within intratumorally heterogeneous meningiomas predicts tumor recurrence","volume":"39","author":"Urbschat","year":"2011","journal-title":"Int J Oncol."},{"issue":"34","key":"2025021113135005800_CIT0069","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol."},{"key":"2025021113135005800_CIT0070","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.1038\/ncomms14433","article-title":"Integrated genomic analyses of de novo pathways underlying atypical meningiomas","volume":"8","author":"Harmanci","year":"2017","journal-title":"Nat Commun."},{"issue":"4","key":"2025021113135005800_CIT0071","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1215\/15228517-2007-026","article-title":"Early recurrences in histologically benign\/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone","volume":"9","author":"Maillo","year":"2007","journal-title":"Neuro Oncol."},{"issue":"5","key":"2025021113135005800_CIT0072","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/not325","article-title":"Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype","volume":"16","author":"Domingues","year":"2014","journal-title":"Neuro Oncol."},{"issue":"17","key":"2025021113135005800_CIT0073","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1200\/JCO.2003.07.156","article-title":"New classification scheme for the prognostic stratification of meningioma on the basis of chromosome 14 abnormalities, patient age, and tumor histopathology","volume":"21","author":"Maillo","year":"2003","journal-title":"J Clin Oncol."},{"issue":"21","key":"2025021113135005800_CIT0074","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.18632\/oncotarget.2517","article-title":"Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5","volume":"5","author":"Abedalthagafi","year":"2014","journal-title":"Oncotarget."},{"key":"2025021113135005800_CIT0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41525-017-0023-6","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genom Med."},{"issue":"7","key":"2025021113135005800_CIT0076","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/ijc.22855","article-title":"Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas","volume":"121","author":"Ketter","year":"2007","journal-title":"Int J Cancer."},{"issue":"1","key":"2025021113135005800_CIT0077","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41467-020-18582-7","article-title":"Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma","volume":"11","author":"Magill","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"2025021113135005800_CIT0078","first-page":"vdad004","article-title":"Genomic markers of recurrence risk in atypical meningioma following gross total resection","volume":"5","author":"Vaubel","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"6","key":"2025021113135005800_CIT0079","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00401-023-02642-5","article-title":"Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: Comprehensive molecular analysis of EORTC 22042-26042","volume":"146","author":"Maas","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2025021113135005800_CIT0080","doi-asserted-by":"crossref","first-page":"e13132","DOI":"10.1111\/bpa.13132","article-title":"Clinical implementation of integrated molecular-morphologic risk prediction for meningioma","volume":"33","author":"Hielscher","year":"2023","journal-title":"Brain Pathol."},{"issue":"3","key":"2025021113135005800_CIT0081","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00401-022-02455-y","article-title":"Intratumor and informatic heterogeneity influence meningioma molecular classification","volume":"144","author":"Vasudevan","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2025021113135005800_CIT0082","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00401-017-1678-x","article-title":"Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma","volume":"133","author":"Olar","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"13","key":"2025021113135005800_CIT0083","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.celrep.2018.03.013","article-title":"Comprehensive molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation","volume":"22","author":"Vasudevan","year":"2018","journal-title":"Cell Rep."},{"issue":"7","key":"2025021113135005800_CIT0084","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: Development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol."},{"issue":"5","key":"2025021113135005800_CIT0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet."},{"issue":"3","key":"2025021113135005800_CIT0086","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2023","journal-title":"Neuro Oncol."},{"issue":"43","key":"2025021113135005800_CIT0087","doi-asserted-by":"crossref","first-page":"21715","DOI":"10.1073\/pnas.1912858116","article-title":"Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors","volume":"116","author":"Patel","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2025021113135005800_CIT0088","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/neuros\/nyaa355","article-title":"A prognostic gene-expression signature and risk score for meningioma recurrence after resection","volume":"88","author":"Chen","year":"2020","journal-title":"Neurosurgery."},{"issue":"12","key":"2025021113135005800_CIT0089","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"issue":"5","key":"2025021113135005800_CIT0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/neuonc\/noab243","article-title":"Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)","volume":"24","author":"Preusser","year":"2022","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae170\/58971762\/noae170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/319\/58971762\/noae170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/319\/58971762\/noae170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:14:25Z","timestamp":1739261665000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/2\/319\/7745776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":90,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,30]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae170","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,8,30]]}}}